|
TMP
|
μl/disc
|
Gram positive
|
Gram negative
|
|---|
|
S.aureus
|
E.coli
|
K. pneumoniae
|
|---|
|
ATCC
|
MRSA
|
ATCC
|
MDR
|
ATCC
|
MDR
|
|---|
|
T. schimper + B.cuspidata (1:1 ratio)
|
5
|
19 ± 1.0
|
18 ± 1.2
|
20 ± 1.0
|
21 ± 0.1
|
27 ± 1.0
|
27 ± 0.8#
|
|
10
|
29 ± 1.2
|
29 ± 0.5**
|
23 ± 1.2
|
25 ± 0.1¥
|
29 ± 1.2
|
28 ± 0.3#
|
|
15
|
33 ± 0.1
|
33 ± 0.6**
|
28 ± 0.1
|
26 ± 0.5¥
|
33 ± 0.7
|
34 ± 0.1##
|
|
20
|
38 ± 0.3
|
39 ± 0.8***
|
29 ± 0.1
|
29 ± 0.8¥¥
|
35 ± 1.4
|
35 ± 0.5##
|
|
B. cuspidata + B. ogadensis (1:1 ratio)
|
5
|
20 ± 0.4
|
20 ± 0.1
|
16 ± 0.4
|
15 ± 0.9
|
19 ± 0.7
|
15 ± 0.4
|
|
10
|
25 ± 0.5
|
26 ± 0.3*
|
18 ± 0.6
|
23 ± 0.2
|
24 ± 0.4
|
23 ± 0.2
|
|
15
|
28 ± 0.3
|
27 ± 0.3**
|
24 ± 0.5
|
26 ± 0.4¥
|
27 ± 1.2
|
26 ± 0.4#
|
|
20
|
32 ± 0.1
|
32 ± 0.1***
|
26 ± 0.8
|
27 ± 0.1¥
|
29 ± 0.1
|
29 ± 0.2##
|
|
B. ogadensis + T. schimper (1:1 ratio)
|
5
|
11 ± 0.6
|
11 ± 0.3
|
9 ± 0.1
|
10 ± 0.1
|
12 ± 0.4
|
12 ± 0.4
|
|
10
|
14 ± 0.3
|
15 ± 0.7
|
13 ± 0.8
|
13 ± 0.8
|
15 ± 0.6
|
16 ± 0.6
|
|
15
|
16 ± 0.4
|
16 ± 0.1
|
15 ± 0.5
|
14 ± 0.4
|
19 ± 0.7
|
20 ± 0.7
|
|
20
|
19 ± 0.1
|
19 ± 0.8
|
17 ± 0.7
|
21 ± 0.3
|
21 ± 0.2
|
20 ± 0.7
|
|
Modern drug
|
24 ± 0.8
|
11 ± 1.3(R)
|
22 ± 0.4
|
17 ± 0.4(R)
|
23 ± 0.7
|
17 ± 0.2(R)
|
- The values represent mean ± standard deviation, N NO inhibition zone, R Resistant (≤16 mm IZ), S=Susceptible (≥ 21 mm IZ). Where, *P < 0.05, **P < 0.01, ***P < 0.001when compared to cefoxitin treated MRSA. While, #P < 0.05, ##P < 0.01when compared to modern drug treated K. pneumoniae and ¥ P < 0.05, ¥¥P < 0.01 when compared to modern drug treated E. coli
